FTRE 📈 Fortrea Holdings - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US34965K1079

FTRE: Biopharmaceuticals, Medical Devices, Clinical Trials, Technology Solutions

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina. Web URL: https://www.fortrea.com

Additional Sources for FTRE Stock

FTRE Stock Overview

Market Cap in USD 1,794m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 2023-07-03

FTRE Stock Ratings

Growth 5y -74.1%
Fundamental -44.4%
Dividend -
Rel. Strength Industry -897
Analysts 3.17/5
Fair Price Momentum 15.90 USD
Fair Price DCF 44.51 USD

FTRE Dividends

No Dividends Paid

FTRE Growth Ratios

Growth Correlation 3m 32.4%
Growth Correlation 12m -85.6%
Growth Correlation 5y -62.3%
CAGR 5y -25.43%
CAGR/Mean DD 5y -0.97
Sharpe Ratio 12m -0.74
Alpha -86.30
Beta 1.73
Volatility 75.15%
Current Volume 2653.8k
Average Volume 20d 1307.3k
What is the price of FTRE stocks?
As of December 21, 2024, the stock is trading at USD 19.26 with a total of 2,653,832 shares traded.
Over the past week, the price has changed by -3.70%, over one month by +0.57%, over three months by -19.41% and over the past year by -40.99%.
Is Fortrea Holdings a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Fortrea Holdings (NASDAQ:FTRE) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.39 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FTRE as of December 2024 is 15.90. This means that FTRE is currently overvalued and has a potential downside of -17.45%.
Is FTRE a buy, sell or hold?
Fortrea Holdings has received a consensus analysts rating of 3.17. Therefor, it is recommend to hold FTRE.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 9
  • Sell: 1
  • Strong Sell: 0
What are the forecast for FTRE stock price target?
According to ValueRays Forecast Model, FTRE Fortrea Holdings will be worth about 17.2 in December 2025. The stock is currently trading at 19.26. This means that the stock has a potential downside of -10.85%.
Issuer Forecast Upside
Wallstreet Target Price 23.4 21.5%
Analysts Target Price 28.7 48.9%
ValueRay Target Price 17.2 -10.9%